Quick Answer
Orchestra BioMed Holdings, Inc. reported Total Assets of $114.86 million for the year ending 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +50.8% in Total Assets from 2024 to 2025.
- This data is from Orchestra BioMed Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $162.20 million | Q1 2021: $162.10 million | Q2 2021: $162.03 million | Q3 2021: $161.88 million | Q1 2022: $161.53 million | Q2 2022: $161.58 million | Q3 2022: $68.65 million | Q1 2023: $136.28 million | Q2 2023: $125.88 million | Q3 2023: $116.36 million | Q1 2024: $82.63 million | Q2 2024: $72.38 million | Q3 2024: $75.32 million | Q1 2025: $59.05 million | Q2 2025: $42.83 million | Q3 2025: $104.81 million.
- Over the full 6 years of available data (2020 to 2025), Orchestra BioMed Holdings, Inc.'s Total Assets has declined by 29.2%.
- Historical annual values: Fiscal year 2025: $114.86 million | Fiscal year 2024: $76.17 million | Fiscal year 2023: $95.21 million | Fiscal year 2022: $95.57 million | Fiscal year 2021: $161.82 million | Fiscal year 2020: $162.16 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: